Biotricity Inc. has received its 510(k) clearance for its Bioflux device with the FDA. This latest 510(k) is the final FDA requirement needed for Biotricity to bring to market Bioflux in the US. Bioflux consists of a proprietary mobile ECG monitoring device and an ECG viewer software package, that enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease by detecting and transmitting probable arr...